BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dixon ML, Leavenworth JD, Leavenworth JW. Lineage Reprogramming of Effector Regulatory T Cells in Cancer. Front Immunol 2021;12:717421. [PMID: 34394124 DOI: 10.3389/fimmu.2021.717421] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Li J, Li X, Guo Q. Drug Resistance in Cancers: A Free Pass for Bullying. Cells 2022;11:3383. [DOI: 10.3390/cells11213383] [Reference Citation Analysis]
2 Yaping W, Zhe W, Zhuling C, Ruolei L, Pengyu F, Lili G, Cheng J, Bo Z, Liuyin L, Guangdong H, Yaoling W, Niuniu H, Rui L. The soldiers needed to be awakened: Tumor-infiltrating immune cells. Front Genet 2022;13:988703. [DOI: 10.3389/fgene.2022.988703] [Reference Citation Analysis]
3 Seals MR, Moran MM, Leavenworth JD, Leavenworth JW. Contribution of Dysregulated B-Cells and IgE Antibody Responses to Multiple Sclerosis. Front Immunol 2022;13:900117. [DOI: 10.3389/fimmu.2022.900117] [Reference Citation Analysis]
4 Dixon ML, Luo L, Ghosh S, Grimes JM, Leavenworth JD, Leavenworth JW. Remodeling of the tumor microenvironment via disrupting Blimp1+ effector Treg activity augments response to anti-PD-1 blockade. Mol Cancer 2021;20:150. [PMID: 34798898 DOI: 10.1186/s12943-021-01450-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]